OPKO Health (OPK) Projected to Announce Earnings on Monday

OPKO Health (NASDAQ:OPK) is projected to post its Q2 2026 results after the market closes on Monday, July 27th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $131.2330 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Monday, July 27, 2026 at 4:30 PM ET.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $124.20 million during the quarter, compared to analysts’ expectations of $130.51 million. OPKO Health had a negative return on equity of 16.78% and a negative net margin of 36.63%.The firm’s quarterly revenue was down 17.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.10) earnings per share. On average, analysts expect OPKO Health to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

OPKO Health Price Performance

Shares of NASDAQ:OPK opened at $1.22 on Friday. The company has a 50 day moving average of $1.37 and a 200 day moving average of $1.26. The company has a current ratio of 3.61, a quick ratio of 3.17 and a debt-to-equity ratio of 0.28. The stock has a market cap of $921.21 million, a P/E ratio of -4.52 and a beta of 1.48. OPKO Health has a 12 month low of $0.98 and a 12 month high of $1.61.

Institutional Trading of OPKO Health

Large investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC lifted its holdings in shares of OPKO Health by 2,369.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 119,223 shares of the biotechnology company’s stock worth $198,000 after buying an additional 114,396 shares during the period. AQR Capital Management LLC lifted its stake in OPKO Health by 466.7% in the first quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company’s stock worth $2,671,000 after acquiring an additional 1,324,988 shares during the period. Millennium Management LLC grew its holdings in OPKO Health by 39.2% during the 1st quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock worth $10,602,000 after acquiring an additional 1,798,385 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of OPKO Health by 4.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,001,214 shares of the biotechnology company’s stock valued at $6,642,000 after purchasing an additional 161,394 shares in the last quarter. Finally, Caxton Associates LLP purchased a new stake in shares of OPKO Health in the 1st quarter worth approximately $130,000. Institutional investors own 64.63% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on OPK shares. Wall Street Zen upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Barrington Research lowered shares of OPKO Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 29th. Finally, Weiss Ratings upgraded shares of OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. Four research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $1.55.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.